Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30388593 | 0.91 | NFE2L2 (0.42) | NFE2L2KCNA5SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL221588 | 0.91 | NFE2L2 (0.42) | NFE2L2KCNA5SMN1; SMN2RAB9ANPC1 | |
| Chlorotriphenylmethane SCHEMBL27667603 | 0.90 | NFE2L2 (0.41) | NFE2L2KCNA5SMN1; SMN2RAB9ANPC1 | |
| Pyridine SCHEMBL6531369 | 0.85 | CYP19A1 (0.42) | CYP19A1KCNA5SMN1; SMN2ALDH1A1 | |
| SCHEMBL2445301 | 0.79 | SMN1; SMN2 (0.39) | KDM4EMAPTHSD17B10CYP19A1NFE2L2 | |
| SCHEMBL221217 | 0.78 | CA1 (0.46) | CYP19A1NFE2L2L3MBTL1KCNA5ALDH1A1 | |
| SCHEMBL16675115 | 0.75 | NFE2L2 (0.45) | NFE2L2POLBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL221587 | 0.74 | CA1 (0.46) | CYP19A1NFE2L2L3MBTL1KCNA5ALDH1A1 | |
| SCHEMBL9013823 | 0.73 | NFE2L2 (0.44) | NFE2L2KCNA5SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL31430103 | 0.73 | NFE2L2 (0.44) | NFE2L2KCNA5SMN1; SMN2NPC1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050074771-A1 | Carbamate-derivatized nucleosides and oligonucleosides | ISIS PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| US-6803198-B2 | COMPOUND FOR USE IN HUMAN THERAPEUTICS AND DIAGNOSTICS | ISIS PHARMACEUTICALS, INC. | 2004-10-12 | — | — | US | disclosed |
| US-6660720-B2 | Targeted oligonucleotide conjugates | ISIS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030166896-A1 | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. | 2003-09-04 | — | — | US | disclosed |
| US-20030130220-A1 | Targeted oligonucleotide conjugates | IONIS PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6528639-B2 | Active ribozyme | RIBOZYME PHARMACEUTICALS, INC. | 2003-03-04 | — | — | US | disclosed |
| US-20030039977-A1 | Carbamate-derivatized nucleosides and oligonucleosides | ISIS PHARMACEUTICALS, INC. | 2003-02-27 | — | — | US | disclosed |
| US-6525031-B2 | Complexes carry primary moieties, chiefly therapeutic, to target cells; feature cell surface receptor ligands to provide specificity; ligands are preferably bound to primary moieties through polyfunctional manifold compounds. | ISIS PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
| US-20020058639-A1 | Targeted oligonucleotide conjugates | ISIS PHARMACEUTICALS, INC. | 2002-05-16 | — | — | US | disclosed |
| US-6322987-B1 | FOR TREATING AN ANIMAL HAVING A DISEASE CHARACTERIZED BY UNDESIRED PRODUCTION OF PROTEIN | ISIS PHARMACEUTICALS, INC. | 2001-11-27 | — | — | US | disclosed |
| EP-0983291-A1 | CARBAMATE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1999065925-A1 | TARGETED OLIGONUCLEOTIDE CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1999-12-23 | — | — | WO | disclosed |
| US-5891684-A | RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-04-06 | — | — | US | disclosed |
| US-5879938-A | RIBOZYME WITH INCREASED ACTIVITY BY SUBSTITUTION OF MODIFIED NUCLEOTIDE INTO SUBSTRATE BINDING ARM OR CATALYTIC CORE | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-03-09 | — | — | US | disclosed |
| US-5767263-A | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-06-16 | — | — | US | disclosed |
| WO-1998011123-A1 | CARBAMATE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1998-03-19 | — | — | WO | disclosed |
| EP-0799313-A2 | METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS, INDUCTION OF GRAFT TOLERANCE AND REVERSAL OF IMMUNE RESPONSES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-10-08 | — | — | EP | disclosed |
| US-5672501-A | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-09-30 | — | — | US | disclosed |
| US-5672511-A | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-09-30 | — | — | US | disclosed |
| WO-1996018736-A2 | METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS, INDUCTION OF GRAFT TOLERANCE AND REVERSAL OF IMMUNE RESPONSES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130220-A1 | Targeted oligonucleotide conjugates | CD47, CD44, FOLR1 | KDM4E 3783/4885MAPT 4329/4885HSD17B10 3969/4885 |
| US-20050074771-A1 | Carbamate-derivatized nucleosides and oligonucleosides | RNGTT, NUDT21, DUT | KDM4E 703/4885MAPT 4490/4885HSD17B10 1607/4885 |
| US-20030039977-A1 | Carbamate-derivatized nucleosides and oligonucleosides | RNGTT, NUDT21, DUT | KDM4E 703/4885MAPT 4490/4885HSD17B10 1607/4885 |
| US-20020058639-A1 | Targeted oligonucleotide conjugates | CD47, CD44, FOLR1 | KDM4E 3783/4885MAPT 4329/4885HSD17B10 3969/4885 |
| US-20030166896-A1 | Base-modified enzymatic nucleic acid | RNASE1, RNGTT, RNASEL | KDM4E 2658/4885MAPT 4272/4885HSD17B10 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.